Skip to main content

Table 1 Exposure of pediatric patients residing in Alabama to individual TNFi and patient-years of exposure for eacha

From: Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study

Medication Number of subjects exposed Total patient-years of exposure
Adalimumab 469 495.3
Certolizumab pegol 9 2.0
Etanercept 324 194.6
Golimumab 6 1.5
Infliximab 527 840.6
All TNFi 1033 1564.3
  1. aBecause many subjects were exposed to more than one TNFi, the total number of subjects does not equal the sum of the subjects for the individual medications